1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evotec SE : Notification and public disclosure of transactions by persons

01/25/2022 | 11:53am EDT


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

25.01.2022 / 17:51
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Werner
Last name(s): Lanthaler

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Evotec SE

b) LEI
529900F9KI6OYITO9B12 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0005664809

b) Nature of the transaction
Exercise against cash settlement (Share Performance Plan)
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
35.3878 EUR 1516614.94 EUR

d) Aggregated information
Price Aggregated volume
35.3878 EUR 1516614.94 EUR

e) Date of the transaction
21/01/2022; UTC+1

f) Place of the transaction
Outside a trading venue



25.01.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

72143  25.01.2022 

fncls.ssp?fn=show_t_gif&application_id=1272700&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about EVOTEC SE
05/19Evotec Working With Almirall to Develop New Therapies for Skin Diseases
MT
05/19Evotec and Almirall enter into a multi-target alliance in medical dermatology
EQ
05/18Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
AQ
05/18EVOTEC : Deutsche Bank maintains a Buy rating
MD
05/17TRANSCRIPT : Evotec SE, Sernova Corp. - M&A Call
CI
05/17Nasdaq-Listed Evotec and Sernova Detail Strategic Partnership For Therapy to Advance 'F..
MT
05/17Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based ..
AQ
05/17EVOTEC : RBC reaffirms its Buy rating
MD
05/17Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
EQ
05/17Evotec SE and Sernova Corp Announces Partnership in the Field of Diabetes
CI
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2022 682 M 720 M 720 M
Net income 2022 -4,70 M -4,96 M -4,96 M
Net cash 2022 88,2 M 93,1 M 93,1 M
P/E ratio 2022 -452x
Yield 2022 -
Capitalization 4 474 M 4 720 M 4 720 M
EV / Sales 2022 6,43x
EV / Sales 2023 5,45x
Nbr of Employees 4 354
Free-Float 87,7%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 25,32 €
Average target price 36,74 €
Spread / Average Target 45,1%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris Löw-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-40.42%4 720
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567